NHLRC4: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: NHLRC4

NCBI ID: G283948

NHLRC4

NHLRC4: A Potential Drug Target and Biomarker for Neurological Disorders

NHLRC4, or NHL repeat containing 4, is a unique DNA sequence that has been identified in the human body. It is found in the blood vessels of the brain and has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease.

The NHLRC4 gene is made up of four copies of a stretch of DNA that is repeated over a period of 3.5 kilobases. This repetition is thought to contribute to the stability and persistence of the gene in the population, as well as to its role in the development of certain neurological disorders.

Recent studies have suggested that NHLRC4 may be a drug target or biomarker for a variety of neurological conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. This is because the expression of the NHLRC4 gene has been shown to be affected by a variety of factors, including age, gender, and environmental factors, and may be a useful target for the development of new treatments for these conditions.

One potential mechanism by which NHLRC4 may be involved in the development of Alzheimer's disease is its role in the formation of neurofibrillary tangles, which are thought to be a hallmark of the disease. Studies have shown that the expression of NHLRC4 is significantly increased in the brains of people with Alzheimer's disease, and that the levels of the gene's repetitive sequence are associated with the severity of the disease.

In addition to its potential role in the development of Alzheimer's disease, NHLRC4 may also be involved in the treatment of other neurological disorders. For example, studies have shown that inhibiting the expression of NHLRC4 has the potential to protect against the neurotoxicity of certain drugs, such as those used to treat Parkinson's disease.

Another potential application of NHLRC4 as a drug target is its role in the treatment of multiple sclerosis. MS is a chronic and unpredictable disease that affects the central nervous system and is characterized by the immune system attacking the protective covering of nerve fibers. Studies have shown that the expression of NHLRC4 is increased in the brains of people with MS, and that the gene's repetitive sequence is associated with the severity of the disease.

In addition to its potential role in the treatment of MS, NHLRC4 may also be used as a biomarker to monitor the effectiveness of certain treatments. For example, the levels of NHLRC4 have been shown to be reduced in the brains of people with MS who respond to one of the disease's most common treatments, and this reduction has been associated with improved disability scores.

Overall, NHLRC4 is a unique and promising candidate for drug targeting and biomarker development for a variety of neurological disorders. Further research is needed to fully understand its role in the development and progression of these conditions, as well as its potential as a drug or biomarker.

Protein Name: NHL Repeat Containing 4

The "NHLRC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NHLRC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets